Piramal Pharma to expand injectables portfolio in complex hospital generics business

livemint.com:

Subscribe to enjoy similar stories. Piramal Pharma Ltd, which has a strong presence in the inhaled anaesthetic generics segment in the US and emerging markets, plans to expand its pipeline of injectables to drive growth, chairperson Nandini Piramal told Mint in an interview. The company launched Chlorpromazine Hydrochloride, an injectable used to treat psychiatric disorders, in the US on 22 January.

This is the latest injectable from Piramal Critical Care, the company’s complex hospital generics arm. In 2024, it launched Edaravone injection, used to treat amyotrophic lateral sclerosis (ALS), and a new concentration of Zinc Sulfate for injection, which followed the Pantoprazole Sodium injectable and the Doxycycline injectable in 2023. “There will be growth in inhalation anaesthetics as well as our injectable pain and intrathecal products, but it is a generic business.

We have a good market share already, so we expect there to be more growth coming from these complex injectables that we will add to the portfolio," Piramal said. “We’ll do launches at a variety of timelines. For example, we will do licensing of development projects but also products that are already developed and launched.

So, it will be a mix." The pharma company reported a 14% year-on-year growth in its complex hospital generics business in Q3, with revenue of ₹654 crore, driven largely by strong sales volumes in its inhalation anaesthesia portfolio. The company is the largest seller of Sevoflurane, an inhalation anaesthetic, in the US market with an over 40% market share, as well as an over 70% market share in the US for Intrathecal Baclofen, a muscle relaxant. Sevoflurane makes up about 80% of the global inhalation anaesthesia market since it is potent